Atrial cardiopathy biomarkers and atrial fibrillation in the ARCADIA trial
European Stroke Journal · 01.06.2025 · 10 (2) · 495-501
DOI: 10.1177/23969873241276358 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Stroke Journal, online erschienen am 01.06.2025. Verfasst von Hooman Kamel und 14 weiteren Autor:innen. Beteiligte Einrichtung: Clinical and Translational Neuroscience Unit, Department of Neurology and Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New …. Hauptthemen laut MEDLINE: Atrial Fibrillation, Natriuretic Peptide, Brain, Peptide Fragments, Pyridones. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS, Pfizer, Roche Diagnostics.
Abstract (Originalsprache)
Background
ARCADIA compared apixaban to aspirin for secondary stroke prevention in patients with cryptogenic stroke and atrial cardiopathy. One possible explanation for the neutral result is that biomarkers used did not optimally identify atrial cardiopathy. We examined the relationship between biomarker levels and subsequent detection of AF, the hallmark of atrial cardiopathy.
Methods
Patients were randomized if they met criteria for atrial cardiopathy, defined as P-wave terminal force >5000 μV*ms in ECG lead V1 (PTFV1), NT-proBNP >250 pg/mL, or left atrial diameter index (LADI) ⩾3 cm/m2. For this analysis, the outcome was AF detected per routine care.
Results
Of 3745 patients who consented to screening for atrial cardiopathy, 254 were subsequently diagnosed with AF; 96 before they could be randomized and 158 after randomization. In unadjusted analyses, ln(NT-proBNP) (RR per SD, 1.99; 95% CI, 1.85–2.13), PTFV1 (RR per SD, 1.15; 95% CI, 1.03–1.28) and LADI (RR per SD, 1.34; 95% CI, 1.20–1.50) were associated with AF. In a model containing all 3 biomarkers, demographics, and AF risk factors, age (RR per 10 years, 1.24; 95% CI, 1.09–1.41), ln(NT-proBNP) (RR per SD, 1.88; 95% CI, 1.67–2.11) and LADI (RR per SD, 1.25; 95% CI, 1.14–1.37) were associated with AF. These three variables together had a c-statistic of 0.82 (95% CI, 0.79–0.85) but only modest calibration. Discrimination was attenuated in sensitivity analyses of patients eligible for randomization who may have been more closely followed for AF.
Conclusions
Biomarkers used to identify atrial cardiopathy in ARCADIA were moderately predictive of subsequent AF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical and Translational Neuroscience Unit, Department of Neurology and Feil Family Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, USA.
- Department of Neurology, Columbia University, New York, NY, USA.
- Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
- Departments of Biostatistics, University of Washington, Seattle, WA, USA.
- Neurology, University of Washington, Seattle, WA, USA.
- Medicine, University of Washington, Seattle, WA, USA.
ORCID-Profile: Hooman Kamel
Förderung
- NINDS NIH HHS
- Pfizer
- Roche Diagnostics
- National Institute of Neurological Disorders and Stroke
- Bristol-Myers Squibb
Zitieren
APA
Kamel, H., Elkind, M. S., Kronmal, R. A., Longstreth, W. T., Plummer, P., Aragon Garcia, R., Broderick, J. P., Pauls, Q., Elm, J. J., Nahab, F., Janis, L. S., Di Tullio, M. R., Soliman, E. Z., Healey, J. S., & Tirschwell, D. L. (2025). Atrial cardiopathy biomarkers and atrial fibrillation in the ARCADIA trial. European Stroke Journal, 10(2), 495-501. https://doi.org/10.1177/23969873241276358
Vancouver
Kamel H, Elkind MS, Kronmal RA, Longstreth WT, Plummer P, Aragon Garcia R, et al. Atrial cardiopathy biomarkers and atrial fibrillation in the ARCADIA trial. European Stroke Journal. 2025;10(2):495-501. doi:10.1177/23969873241276358
BibTeX
@article{Kamel2025,
author = {Kamel, Hooman and Elkind, Mitchell Sv and Kronmal, Richard A and Longstreth, W T and Plummer, Pamela and Aragon Garcia, Rebeca and Broderick, Joseph P and Pauls, Qi and Elm, Jordan J and Nahab, Fadi and Janis, L Scott and Di Tullio, Marco R and Soliman, Elsayed Z and Healey, Jeff S and Tirschwell, David L},
title = {Atrial cardiopathy biomarkers and atrial fibrillation in the ARCADIA trial},
journal = {European Stroke Journal},
year = {2025},
volume = {10},
number = {2},
pages = {495--501},
doi = {10.1177/23969873241276358}
}
EUVIMED